Cynapsus Wants To Offer Parkinson’s Patients A Friendlier Apomorphine Option

This article was originally published in The Pink Sheet Daily

10 Jul 2015
News

Executive Summary

Sublingual film formulation of apomorphine, just moving into Phase III, would address “off” episodes with fewer side effect issues and easier administration than the current injectable version.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Canada

Related Companies

Related Deals

Catabasis Pharmaceuticals nets $64.2mm in IPO

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Canada Clinical Trials

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS078677

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS078677

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Cynapsus Wants To Offer Parkinson’s Patients A Friendlier Apomorphine Option

News

Executive Summary

Related Content

Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert